Astellas Pharma Inc.

As of March 31, 2025, Astellas Pharma Inc. carries a market capitalization of 2.59T, placing it among publicly traded companies globally. Its enterprise value stands at 3.20T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Astellas Pharma Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of March 31, 2025, Astellas Pharma Inc. has 1.79B shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Astellas Pharma Inc. maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, Astellas Pharma Inc. recorded an income tax benefit of -15.38B rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, Astellas Pharma Inc.'s stock has gained approximately 53.27% over the past 52 weeks. The 50-day moving average sits at 2,341.23, while the 200-day moving average is 2,315.02.

As of March 31, 2025, Astellas Pharma Inc. holds 218.31B in cash and equivalents against 831.43B in total debt, resulting in a net debt position of 643.05B. Total book value stands at 1.51T, with working capital of 139.74B providing operational flexibility.

These figures cover the twelve months ended March 31, 2025.

Astellas Pharma Inc.'s most recent stock split took place on March 27, 2014 with a 1:5 split ratio.